Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS.
Directly coupled HPLC NMR spectroscopic and HPLC-MS approaches have been used to confirm the identity of four known dimeric impurities in a partially purified batch of fluticasone propionate each at levels of 0.06-0.9% of parent compound based on UV absorption. It is also shown that HPLC NMR spectroscopy of the main drug peak in the 'time-slice' mode of operation, in which the elution of the HPLC peak is sampled a short time intervals, can be used to investigate the purity profile of the single HPLC peak detected by UV absorption. These studies show that HPLC-NMR is of considerable value in rapidly assessing HPLC peak purity and hence will be of benefit in providing additional information to support submission for drug registration to regulatory agencies.